United States Patent 7,521,041: Scope, Claim Set, and Muscarinic Antagonist Patent Landscape

US Drug Patent 7,521,041 is directed to a class of muscarinic receptor-antagonizing compounds defined by a broad structural Markush framework and to functional methods for (1) determining antagonist effects in ex vivo or in vitro biological systems and (2) evaluating bronchoconstriction/pulmonary resistance in mammals. The claims are anchored by three mechanistic assay endpoints tied to second messenger or receptor signaling readouts: cAMP accumulation, GTPγS binding, and calcium release, with optional comparative designs for ranking candidate antagonists against the claimed compound. The independent claim set includes method-of-use claims rather than composition-of-matter, but the compound definition appears as a required parameter in each asserted method step.

What is the core claimed invention in US 7,521,041?

1) Compound scope: Markush-defined muscarinic antagonists

Across method claims, the antagonists are defined by a general formula (not fully rendered in the prompt text), with the same variable logic repeated in claims 1, 2, 3, 4, and 5. The compound definition is the gating element that controls infringement because each method claim requires “a muscarinic receptor-antagonizing amount of a compound having the formula … or a pharmaceutically acceptable salt or stereoisomer.”

Key variable constraints shown in the claim text:

a is 0 or 1
R1 is halo
b is 0 or 1
R2 is halo
m is 0 or 1
R4 is hydrogen or (1-4C)alkyl
s is 0, 1, or 2
Ar1 is a phenylene or (3-5C)heteroarylene ring with 1 or 2 heteroatoms independently selected from O, N, S
Ar1 substitution: the phenylene/heteroarylene is substituted with (R5)q where q is 0 or 1-4, and each R5 independently is halo, hydroxy, (1-4C)alkyl, or (1-4C)alkoxy
t is 0, 1, or 2
n is 0 or 1-3
p is 0 or 1
R7 and R8 are each hydrogen or (1-4C)alkyl, where each alkyl may carry 1-5 fluorines
The claim also covers pharmaceutically acceptable salts and stereoisomers

2) Functional scope: antagonist effect readouts

The patent claims three distinct experimental readouts for quantifying muscarinic antagonist activity:

cAMP accumulation inhibition (claims 1, and claim 3 has the GTPγS version; claim 4 uses calcium)
GTPγS binding decrease (claim 3)
calcium release reduction (claim 4)

3) In vivo evaluation pathway

Claim 5 shifts the readout to physiology:

Induce bronchoconstriction
Measure pulmonary resistance
Administer a therapeutically effective amount of the antagonizing compound (or in method language, “a muscarinic receptor-antagonizing amount”)

Which claims define the breadth and which define the “tight” boundaries?

Independent claims

Claim 1: In vitro/ex vivo method quantifying antagonist effects via cAMP
Includes steps (a) agonist only; (b) measure cAMP; (c) agonist + antagonist; (d) measure cAMP; (e) compare.
Claim 3: Same experimental logic but with GTPγS binding as the endpoint.
Claim 4: Same experimental logic but with calcium release as endpoint.
Claim 2: A direct in vivo antagonism method (administration to mammal) using the same compound definition (this is the closest to a treatment claim, though still tied to “method for antagonizing a muscarinic receptor” rather than a specific disease indication).
Claim 5: A functional mammalian bronchoconstriction method with pulmonary resistance.

Dependent claims that expand experimental configurations

The dependent claim set broadens applicability across biological matrices and experimental variants:

Claim 6: biological system/sample can be cells, cellular extracts, plasma membranes, tissue samples, and mammals
Claim 7-8: adds a third sample and a test compound for comparative ranking against the claimed antagonist, focused on “about equal or superior blockade” of agonist-mediated cAMP inhibition.
Claim 11-12: analogous third-sample comparator for the GTPγS assay.
Claim 14-15: analogous third-sample comparator for calcium release.
Claims 9, 10, 13: agonists enumerated as oxotremorine, acetylcholine, pilocarpine, methacholine
Claim 16: bronchoconstriction can be induced by administering acetylcholine
Claims 17-21: explicit narrower structural embodiments using specific values of Markush variables (a, b, m, s, t, Ar1 choice, para substitution, n value, R8 hydrogen, etc.)
Claim 22: explicit named compound embodiment:
biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester (and pharmaceutically acceptable salt)

What is the practical claim scope for competitors?

A) Infringement trigger: use of a covered compound plus specific assay steps

Because this patent is framed as method-of-use with the compound definition embedded in method steps, infringement requires two conditions in practice:

The compound administered/used is within the defined structural genus (including salts/stereoisomers).
The method uses one of the claimed experimental/in vivo workflows:
- cAMP assay with muscarinic agonist +/- antagonist
- GTPγS binding assay with muscarinic agonist +/- antagonist
- calcium release assay with muscarinic agonist +/- antagonist
- mammalian bronchoconstriction with pulmonary resistance

B) Scope is controlled by the Markush genus, not by the assay

The assay logic is standard across claims: compare agonist-alone vs agonist+antagonist. That makes the structural definition the main boundary.

C) Broad sample types and comparator variants increase enforcement surface

Claim 6 expands to cells, extracts, membranes, tissues, and mammals. Claims 7/11/14 add test-compound ranking designs that mimic typical hit-to-lead workflows.

How do the claim families map to pharmacology endpoints?

Claim	Antagonist effect endpoint	Biological mechanism proxy	Experimental pattern
1	cAMP produced	muscarinic signaling impacting adenylate cyclase pathway readout	agonist only vs agonist + antagonist; compare cAMP
3	GTPγS binding	G-protein activation state via binding	agonist +/− antagonist; compare binding
4	calcium released	downstream calcium mobilization	agonist only vs agonist + antagonist; compare calcium
5	pulmonary resistance after bronchoconstriction	functional airway constriction readout	administer compound; induce constriction (incl. ACh); measure resistance
2	“antagonizing” muscarinic receptor in mammal	treatment-like use, without explicit disease	administer therapeutically effective amount

This is a multi-endpoint strategy. A competitor using a covered compound in a different assay might avoid literal claim coverage if the assay steps do not match. But the three major second messenger and receptor signaling readouts substantially cover common in vitro pharmacology protocols.

Key “narrowing” dependent features: what structures are explicitly carved in?

Dependent claims 17-21 select specific parameter values that narrow the genus into defined subgenera and positioning constraints. The text provides the following tightening points:

Claim 17: a = 0 and b = 0
Claim 18: m = 0, t = 1, plus an implicit “a and b each represent 0” through its dependency
Claim 19: the —CONR7R8 group is in the para position and n = 2
Claim 20: Ar1 is limited to:
- phen-1,3-ylene
- phen-1,4-ylene
- 2,4-thienylene
- 2,5-thienylene and optionally substituted with one or two R5 substituents
Claim 21: a fully specified embodiment:
- a = 0; b = 0; m = 0; s = 0; t = 1
- Ar1 = phen-1,4-ylene optionally substituted with 1 or 2 R5
- n = 2
- —CONR7R8 group in para position
- R8 = hydrogen

These sub-clauses reduce arguments that a competitor’s structure is “almost” within scope; they show the patentee contemplated and claimed specific configurations.

Named compound anchor: what does Claim 22 do to enforceability?

Claim 22 names a specific compound (structure described in systematic chemical form) and/or its pharmaceutically acceptable salt.

Named-structure coverage creates two practical effects in a landscape:

It signals which actual lead molecule(s) the Markush language was intended to cover.
It allows enforceability through a direct mapping: if a commercial candidate matches the named structure (or a salt/stereoisomer), the claims are straightforward.

Where does US 7,521,041 sit in a broader muscarinic antagonist patent landscape?

1) Landscape posture: pharmacology and in vivo function rather than standalone composition claims

The claim set is built around:

antagonist activity measurement workflows (cAMP, GTPγS, calcium)
in vivo bronchoconstriction and pulmonary resistance

This positions the patent as a functional enforcement tool against developers who conduct these standard translational studies using covered compounds, salts, or stereoisomers.

2) Typical overlap with other muscarinic antagonist IP

In this therapeutic area, other patents commonly claim:

compositions/formulations (dose forms, inhaled formulations, controlled release)
specific compounds (composition-of-matter genera)
specific indications (diseases) and dosing regimens
biomarkers, patient selection, and dosing titration methods

US 7,521,041 differs by tying coverage to:

a defined compound genus
standardized pharmacology assays and functional bronchoconstriction readouts
ranking of test compounds against the claimed antagonist

As a result, even when composition-of-matter patents expire or do not cover a competitor’s exact entity, a developer can still face method-of-use exposure if their internal testing aligns with the claimed assay logic using a covered compound.

3) Enforcement surface is wide because the assay language is generic

Because claim steps use high-level descriptions:

“contacting” samples with agonist and antagonist
“measuring” cAMP/GTPγS/calcium
comparing amounts

the patent can apply across many lab implementations without needing unusual reagents or specialized detection hardware. The gating element remains whether the antagonist compound used is within the structural genus.

Claim-by-claim scope summary (what each claim covers in business terms)

cAMP inhibition assay method using the defined antagonist genus.
In vivo muscarinic antagonism: administration of covered compound in mammals.
GTPγS binding antagonism assay using defined antagonist genus.
Calcium release antagonism assay using defined antagonist genus.
Bronchoconstriction/pulmonary resistance in mammals using defined antagonist genus.
Matrix breadth: cells, extracts, membranes, tissues, mammals.
Third compound comparative cAMP ranking vs claimed antagonist.
Ranking threshold: “about equal or superior” blockade of agonist-mediated inhibition of cAMP accumulation.
Agonist list for claim 1: oxotremorine, acetylcholine, pilocarpine, methacholine.
Same agonist list for claim 2 (in vivo method context).
Third compound comparative GTPγS ranking vs claimed antagonist.
Ranking threshold for GTPγS blockade.
Agonist list for claim 4.
Third compound comparative calcium ranking vs claimed antagonist.
Ranking threshold for calcium release blockade.
Bronchoconstriction induction: acetylcholine administration. 17-21. Structural tightening subsets (specific Markush values and positional constraints).
Named compound embodiment for direct mapping.

Key takeaways

US 7,521,041 covers muscarinic antagonism through a compound genus plus functional assay/in vivo workflows, not only via a direct treatment claim.
The three independent pharmacology claims anchor on cAMP, GTPγS binding, and calcium release, each using an agonist + antagonist comparison design.
Claim 5 extends enforceability into in vivo airway physiology via bronchoconstriction and pulmonary resistance.
Dependent comparative claims (7/11/14) broaden practical exposure to typical drug-discovery screens that benchmark test compounds against a reference antagonist.
The genus includes explicit narrowing embodiments (17-21) and a named compound (22), which strengthens literal infringement mapping if a candidate matches.

FAQs

1) Is US 7,521,041 a composition-of-matter patent?
No. The claims are primarily methods of determining effects and methods of antagonizing with the covered compounds defined as required parameters in method steps.

2) What are the assay endpoints that define the strongest literal scope?
The strongest endpoints in the claim set are cAMP accumulation, GTPγS binding, and calcium release, plus pulmonary resistance in a bronchoconstriction model.

3) Do the claims require any particular muscarinic agonist?
No for the independent claim language. But dependent claims specify agonists as oxotremorine, acetylcholine, pilocarpine, and methacholine.

4) Can competitors avoid exposure by changing the biological matrix?
Claim 6 covers cells, cellular extracts, plasma membranes, tissue samples, and mammals, so changing to another covered matrix may not avoid literal coverage if the rest of the method matches.

5) What is the impact of the named compound in Claim 22?
Claim 22 provides a direct embodiment of at least one specific antagonist structure, improving enforceability if a developer’s candidate matches that structure or a covered salt/stereoisomer.

References (APA)

[1] United States Patent No. 7,521,041. (n.d.). Method for antagonizing muscarinic receptors and methods for determining effects using muscarinic receptor antagonists.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	048032	⤷ Start Trial
Argentina	104444	⤷ Start Trial
Austria	E395335	⤷ Start Trial
Austria	E467617	⤷ Start Trial
Australia	2005222411	⤷ Start Trial
Brazil	PI0508622	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,521,041

Summary for Patent: 7,521,041